Publication: A functional polymorphism in the IL1B gene promoter, IL1B -31C>T, is not associated with cerebral malaria in Thailand
Issued Date
2005-08-14
Resource Type
ISSN
14752875
14752875
14752875
Other identifier(s)
2-s2.0-25444477280
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Malaria Journal. Vol.4, (2005)
Suggested Citation
Jun Ohashi, Izumi Naka, Akihiro Doi, Jintana Patarapotikul, Hathairad Hananantachai, Noppadon Tangpukdee, Sornchai Looareesuwan, Katsushi Tokunaga A functional polymorphism in the IL1B gene promoter, IL1B -31C>T, is not associated with cerebral malaria in Thailand. Malaria Journal. Vol.4, (2005). doi:10.1186/1475-2875-4-38 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/16562
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A functional polymorphism in the IL1B gene promoter, IL1B -31C>T, is not associated with cerebral malaria in Thailand
Other Contributor(s)
Abstract
Background: IL-1β and IL-1RA levels are higher in the serum of cerebral malaria patients than in patients with mild malaria. Recently, the level of IL1B expression was reported to be influenced by a polymorphism in the promoter of IL1, IL1B -31C>T. Methods: To examine whether polymorphisms in IL1B and IL1RA influence the susceptibility to cerebral malaria, IL1B -31C>T, IL1B 3953C>T, and IL1RA variable number of tandem repeat (VNTR) were analysed in 312 Thai patients with malaria (109 cerebral malaria and 203 mild malaria patients). Results: In this population, IL1B -31C>T and IL1RA VNTRwere detected, while IL1B 3953C>T (i.e., IL1B 3953T) was not observed in the polymorphism screening for 32 patients. Further analyses for IL1B -31C>T and IL1RA VNTR in 110 cerebral malaria and 206 mild malaria patients showed no significant association of these polymorphisms with cerebral malaria. Conclusion: The present results suggest that IL1B -31C>T and IL1RA VNTR polymorphisms do not play a crucial role in susceptibility or resistance to cerebral malaria. © 2005 Ohashi et al; licensee BioMed Central Ltd.